首例实时磁共振引导下特发性流出道室性早搏消融
本文报告一例73岁男性症状性药物难治性流出道室性早搏患者,在1.5-T MRI环境下完全实时磁共振引导下完成射频消融,术中无并发症,PVC完全抑制,30分钟观察及2个月随访无复发,为首例人体实时MR引导心室消融。
要点
- 实时MR引导可实现无辐射环境下心脏解剖与消融灶的可视化。
- 首例人体手术在1.5-T MRI系统下完成,术中无并发症。
- PVC完全抑制,30分钟观察及2个月随访均无复发。
核心结论
- 首例人体病例表明心室消融可完全在实时MR引导下安全有效地完成。
研究设计与样本
- 前瞻性、全球首例滚动入组病例,来自正在进行的VISABL-VT非随机临床试验。
- 手术及分析于2025年4月在配有标准1.5-T MRI套件及专用MR兼容电生理平台的学术三级中心完成。
- 患者为73岁男性,症状性药物难治性流出道室性早搏。
主要发现
- 手术在实时MRI引导下完成,无并发症。
- PVC完全抑制,30分钟观察期间及2个月随访均无复发。
- 标测首先识别右心室流出道后间隔最早激动点,此处消融短暂抑制PVC;后经逆行主动脉途径在左冠窦消融最终消除室早。
- 术后MRI确认消融灶形成。
临床怎么用
- 该技术可在无电离辐射环境下实现心室消融,并利用实时MR直接可视化解剖、基质及消融灶。
- 需使用MR兼容电生理平台、12导联心电图监测记录系统、MR条件除颤器及实时导管追踪系统。
- 术后可通过MRI确认消融灶形成。
局限性
- 本文为单例首例人体病例报告,无法评估广泛临床效用及长期 outcomes。
- 需等待VISABL-VT试验进一步明确临床效用与长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Catheter ablation is a cornerstone therapy for symptomatic ventricular arrhythmias, yet current techniques rely on fluoroscopy and electroanatomic mapping, which provide limited soft-tissue detail and expose patients and staff to ionizing radiation. Real-time magnetic resonance (MR)-guided ablation may overcome these limitations by enabling direct visualization of cardiac anatomy, substrate, and lesion formation, all within a radiation-free environment. OBJECTIVE: To demonstrate the technical feasibility and safety of the first-in-human real-time MR-guided radiofrequency ventricular ablation procedure. DESIGN, SETTING, AND PARTICIPANT: This was a prospective, worldwide-first roll-in case from the ongoing VISABL-VT nonrandomized clinical trial assessing MR-guided radiofrequency ablation of ventricular tachycardia. The procedure and analysis were performed in April 2025 at an academic tertiary care center equipped with a standard 1.5-T MR imaging (MRI) suite and dedicated MR-compatible electrophysiology platform, MR-compatible 12-lead electrocardiographic monitoring and recording system, MR-conditional defibrillator, and real-time catheter tracking integrated with the MRI scanner for synchronized imaging and ablation. The patient was a 73-year-old man with symptomatic, drug-refractory outflow tract premature ventricular complexes (PVCs). INTERVENTION: The ablation was performed under general anesthesia inside the MRI scanner. Intraprocedurally acquired noncontrast 3-dimensional MR angiographic imaging was used to create an anatomical roadmap for the procedure. Real-time catheter tracking and activation mapping were performed using actively tracked diagnostic and ablation catheters. Mapping identified earliest activation first in the posterior septal right ventricular outflow tract, where ablation transiently suppressed PVCs. Ectopy recurred but was ultimately resolved by ablation performed via a retrograde aortic approach in the left coronary cusp. Lesion formation was confirmed via postprocedural MRI. MAIN OUTCOMES AND MEASURES: Suppression of PVCs and presence or absence of procedural complications. RESULTS: The procedure was performed under real-time MRI guidance without complications. PVCs were completely suppressed, with no recurrence during 30-minute observation or at 2-month follow-up. CONCLUSIONS: This first-in-human case demonstrates that ventricular ablation can be safely and effectively performed entirely under real-time MR guidance. Further evidence from the VISABL-VT trial will clarify clinical utility and long-term outcomes.
引用
- Götte MJW, Hopman LHGA, Bhagirath P, et al. First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes. JAMA Cardiol. 2025. PMID: 40960845. doi:10.1001/jamacardio.2025.3000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。